Yunxia Zuo

Summary

Publications

  1. ncbi Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
    Zuo Yunxia
    Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai Medical School, Shanghai 200032, PR China
    BMC Med Genet 11:34. 2010
  2. ncbi Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
    Jin Li
    Department of Medical Oncology, Fudan University Shanghai Cancer Center, PR China
    BMC Cancer 10:529. 2010

Detail Information

Publications2

  1. ncbi Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
    Zuo Yunxia
    Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai Medical School, Shanghai 200032, PR China
    BMC Med Genet 11:34. 2010
    ..Data on the gene mutation status of EGFR and K-ras in Chinese patients with CRC are limited...
  2. ncbi Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
    Jin Li
    Department of Medical Oncology, Fudan University Shanghai Cancer Center, PR China
    BMC Cancer 10:529. 2010
    ..The study was conducted to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic variables, and antitumor activity in advanced solid malignancies...